+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.

Age: 18Years - 80YearsAll GendersPhase 3
109 locations
P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.

Age: 18Years +All GendersPhase Not Applicable
101 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.

Age: 55Years +All GendersPhase Not Applicable
125 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
119 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.

Age: 12Years +All GendersPhase 3
202 locations
E

Actively Recruiting

Bipolar disorder is a serious and chronic mood condition affecting both adults and pediatric populations in the United States. This research aims to evaluate the safety and effectiveness of Icalcaprant in treating adults diagnosed with bipolar I or II disorder, focusing on depressive episodes. The study is a phase 2, randomized, placebo-controlled trial enrolling about 195 adults across approximately 35 sites. Participants will be randomly assigned to one of three groups two different doses of oral Icalcaprant or a matching placebo. They will take the assigned oral capsules once daily for six weeks. After the treatment period, there will be a four-week safety follow-up to monitor participants health. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. The main outcomes measured include changes in depression severity using the Montgomery-sberg Depression Rating Scale and monitoring adverse events throughout the treatment and follow-up periods. This study is sponsored by AbbVie and aims to better understand treatment options for bipolar depression.

Age: 18Years - 65YearsAll GendersPhase 2
33 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 1815368 in adults aged 18 and older who have a specific eye condition called centre-involved diabetic macular edema CI-DME, a type of diabetic macular edema. The purpose is to determine if BI 1815368 helps improve vision and to identify the best dose. This randomized, double-masked, placebo-controlled Phase 2 trial is sponsored by Boehringer Ingelheim. The study has two parts. In the first part, participants are randomly assigned to take either BI 1815368 tablets or placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take tablets twice daily for about 11 months. Participants stay in the study for about one year, visiting the study site at least 16 times. Those taking metformin have three extra visits. At each visit, doctors check vision, record any health issues, and take detailed pictures of the eye using advanced imaging. Researchers compare vision changes over time between groups to assess the medicines effect. Safety and tolerability are also monitored throughout the study.

Age: 18Years +All GendersPhase 2
97 locations
R

Actively Recruiting

This observational study is focused on collecting data about the performance of CERAMENT BONE VOID FILLER, a synthetic biphasic bone graft substitute, when used in typical medical practice for orthopedic disorders. The study is sponsored by BONESUPPORT AB and aims to gather information on device performance and patient outcomes to understand its use in real-world settings. Participants will receive CERAMENT BVF as part of their treatment at approved healthcare centers following the products instructions for use. Data collection includes monitoring unexpected device performance, complaints, adverse events, and serious adverse events during surgery and continuing up to 18 months after treatment. Radiological assessments, pain scores, and quality of life evaluations will be conducted at intervals throughout the study. During the study, participants will undergo scheduled reviews at 6, 12, and 18 months to assess device-related outcomes and healing progress using imaging and questionnaires. Researchers will track safety events and gather patient-reported outcomes such as pain levels and quality of life. Participation involves following up with healthcare providers over this period to provide ongoing data for comprehensive evaluation of the devices performance.

Age: 18Years +All Genders
13 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations

1-10 of 18

1